{"analyses":[{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.62","estimateComment":"Ripretinib: Placebo; based on stratified Cox Proportional Hazards Regression Model using randomization stratification factors \\[prior lines of therapy (3 versus ≥4); ECOG (0 versus 1 or 2)\\]","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","pValueComment":"Not evaluated for statistical significance as a result of the sequential testing procedure for the secondary endpoints of ORR and OS.","paramType":"Hazard Ratio (HR)","paramValue":"0.36","statisticalComment":"Strata: prior lines of therapy (3 versus ≥4); ECOG (0 versus 1 or 2)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.6","upperLimit":"65.6","value":"65.6"},{"groupId":"OG001","lowerLimit":"17.9","upperLimit":"50.4","value":"28.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the interval between the date of randomization until the date of death or the date of last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG000","title":"Ripretinib"},{"description":"Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death from any cause [through database cutoff 31-May-2019 (up to approximately 15 months)].","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"weeks"}